Adcentrx Therapeutics is a clinical-stage biotechnology company that focuses on developing innovative protein conjugate therapeutics, particularly antibody-drug conjugates (ADCs), for cancer and other serious diseases. The company aims to enhance patient treatment options by merging the targeting precision of biologics with the therapeutic potency of small molecule payloads. Adcentrx is committed to creating first-in-class and best-in-class therapies that expand the therapeutic window for patients, addressing specific challenges associated with previous generations of conjugates through a comprehensive approach known as the "Conjugate Toolbox."

The Adcentrx Toolbox includes critical components such as the targeting moiety, linker, payload, and conjugation technology, which are optimized to improve the stability and efficacy of ADCs. A key innovation is the i-Conjugation® technology, which enhances conjugate stability in circulation, leading to improved payload delivery and better tumor penetration. Additionally, Adcentrx's design strategies aim to maximize the "bystander effect," allowing treatment to impact heterogeneous tumors effectively. The company also emphasizes efficient manufacturing processes to ensure reproducibility and cost-effectiveness, addressing common challenges in the production of ADCs.

United States

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Adcentrx Therapeutics

Company Details